share_log

翰森製藥：自願公告 - 根據受限制股份單位計劃購買股份

HANSOH PHARMA: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME

香港交易所 ·  Dec 29, 2023 05:38
Summary by Moomoo AI
翰森製藥集團有限公司（「翰森製藥」）於2023年12月公布，根據其受限制股份單位計劃，已於2023年12月21日至22日間購入1,280,000股股份。該批股份的平均代價約為13.8252港元，總代價達17,696,236.00港元。此次股份購入後，受限制股份單位受託人持有的股份數目增至9,614,700股。翰森製藥表示，董事會將繼續根據市場情況，全權酌情決定未來是否繼續購買股份及授予受限制股份單位。
翰森製藥集團有限公司（「翰森製藥」）於2023年12月公布，根據其受限制股份單位計劃，已於2023年12月21日至22日間購入1,280,000股股份。該批股份的平均代價約為13.8252港元，總代價達17,696,236.00港元。此次股份購入後，受限制股份單位受託人持有的股份數目增至9,614,700股。翰森製藥表示，董事會將繼續根據市場情況，全權酌情決定未來是否繼續購買股份及授予受限制股份單位。
HANSEN PHARMACEUTICAL GROUP LIMITED (“HANSEN PHARMACEUTICALS”) ANNOUNCED IN DECEMBER 2023 THAT IT HAS PURCHASED 1,280,000 SHARES FROM DECEMBER 21 TO 22, 2023 UNDER ITS RESTRICTED SHARE PLAN. The average price of the lot is approximately HK$13.8252 and the total price is HK$17,696,236.00. Following this share repurchase, the number of shares held by the Trustees of the Restricted Share Units increased to 9,614,700 shares. Johnson Pharmaceuticals stated that the Board of Directors will continue to decide, in its sole discretion, whether or not to continue to purchase shares and grant restricted units in the future, in accordance with market conditions.
HANSEN PHARMACEUTICAL GROUP LIMITED (“HANSEN PHARMACEUTICALS”) ANNOUNCED IN DECEMBER 2023 THAT IT HAS PURCHASED 1,280,000 SHARES FROM DECEMBER 21 TO 22, 2023 UNDER ITS RESTRICTED SHARE PLAN. The average price of the lot is approximately HK$13.8252 and the total price is HK$17,696,236.00. Following this share repurchase, the number of shares held by the Trustees of the Restricted Share Units increased to 9,614,700 shares. Johnson Pharmaceuticals stated that the Board of Directors will continue to decide, in its sole discretion, whether or not to continue to purchase shares and grant restricted units in the future, in accordance with market conditions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more